follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Alvogen acquires rights to pain medication with $58M in 2012 sales

By

Back to Top Comments Print

News You Can Use

Latest News

advertisement

Global generic pharmaceuticals company Alvogen, with its U.S. base in the Pine Brook section of Montville Township, announced today it has acquired U.S. commercialization rights for a controlled-release pain killer from Florham Park-based Shionogi Inc.

According to the announcement, the nonsteroidal anti-inflammatory Naprelan is manufactured in controlled-release tablets at dosages of 375 mg, 500 mg and 750 mg. The product will be marketed by Almatica Pharma Inc., a subsidiary of Alvogen. In a separate transaction, Alvogen also acquired all rights and interest in the new drug application to the U.S. Food and Drug Administration for Naprelan from Pa.-based Stat-Trade Inc.

Financial terms of the transaction were not disclosed, but Naprelan had annual U.S. sales of $58 million in 2012, the company said in a statement.

The company announced Darren Alkins as its new president in October.

Write to the Editorial Department at editorial@njbiz.com

advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top